Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
Authors:
- Olbjørn KleppOKOlbjørn Klepp
- Arne SolbergASArne Solberg
- Jan-Erik DamberJDJan-Erik Damber
- Anders AngelsenAAAnders Angelsen
- Per FranssonPFPer Fransson
- Jo-Åsmund LundJLJo-Åsmund Lund
- Ilker TasdemirITIlker Tasdemir
- Morten HoyerMHMorten Hoyer
- Fredrik WiklundFWFredrik Wiklund
- Sophie D FossåSFSophie D Fosså
Top Cited Papers
- 1 January 2009
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 373 (9660) , 301-308
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized TrialJNCI: Journal of the National Cancer Institute, 2008
- Regarding the Influence of Adjuvant Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarction: How Real Is the Risk?Journal of Clinical Oncology, 2007
- An Update of the Phase III Trial Comparing Whole Pelvic to Prostate Only Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression: Updated Analysis of RTOG 94-13, With Emphasis on Unexpected Hormone/Radiation InteractionsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapyPsycho-Oncology, 2007
- Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta‐analysis of randomized controlled trialsBJU International, 2007
- Long-Term Followup of a Randomized Study of Locally Advanced Prostate Cancer Treated With Combined Orchiectomy and External Radiotherapy Versus Radiotherapy AloneJournal of Urology, 2006
- Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancerBJU International, 2006
- A Randomised Comparison of Bicalutamide ('Casodex') 150 mg versus Placebo as Immediate Therapy Either Alone or as Adjuvant to Standard Care for Early Non-Metastatic Prostate Cancer First Report from the Scandinavian Prostatic Cancer Group Study No. 6European Urology, 2002
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988